Enfortumab vedotin Disease Interactions
There are 3 disease interactions with enfortumab vedotin.
Enfortumab vedotin (applies to enfortumab vedotin) hepatic impairment
Major Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease
Avoid the use of enfortumab vedotin in patients with moderate or severe hepatic impairment as it has not been studied in these patients. No adjustment in the starting dose is required when treating patients with mild hepatic impairment.
Enfortumab vedotin (applies to enfortumab vedotin) hyperglycemia/diabetes
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Diabetes Mellitus
Hyperglycemia occurred in patients treated with enfortumab vedotin, including death, and diabetic ketoacidosis (DKA) in those with and without preexisting-existing diabetes mellitus. The incidence of Grade 3-4 hyperglycemia increased consistently in patients with higher body mass index and in patients with higher baseline A1C. Closely monitor blood glucose levels in patients with, or at risk for, diabetes mellitus or hyperglycemia. If blood glucose is elevated (>250 mg/dL), withhold treatment.
Enfortumab vedotin (applies to enfortumab vedotin) peripheral neuropathy
Moderate Potential Hazard, Moderate plausibility.
Peripheral neuropathy, predominantly sensory, occurred in 49% of the patients treated with enfortumab vedotin in clinical trials. Peripheral neuropathy occurred in patients with or without preexisting peripheral neuropathy. Monitor patients for symptoms of new or worsening peripheral neuropathy and consider dose interruption or dose reduction when peripheral neuropathy occurs. Permanently discontinue treatment in patients that develop Grade >3 peripheral neuropathy.
Switch to professional interaction data
Enfortumab vedotin drug interactions
There are 482 drug interactions with enfortumab vedotin.
More about enfortumab vedotin
- enfortumab vedotin consumer information
- Check interactions
- Compare alternatives
- Reviews (3)
- Side effects
- Dosage information
- During pregnancy
- Drug class: miscellaneous antineoplastics
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Keytruda
Keytruda is used to treat melanoma, non-small cell lung cancer, malignant pleural mesothelioma ...
Adriamycin
Adriamycin is used for acute lymphoblastic leukemia, acute myeloblastic leukemia, bladder cancer ...
Dupixent
Dupixent is used to treat eczema, eosinophilic or oral-corticosteroid-dependent asthma, chronic ...
Imfinzi
Imfinzi (durvalumab) is an immunotherapy used to treat types of lung cancer (NSCLC, SCLC), bile ...
Padcev
Padcev (enfortumab vedotin) is an antibody-drug conjugate that is given as an intravenous infusion ...
Balversa
Balversa (erdafitinib) is an oral kinase inhibitor that may be used to treat adults with locally ...
Anktiva
Anktiva (N-803) is used to treat specific types of bladder cancer. It is FDA-approved to be used ...
Mitomycin
Mitomycin is used for anal cancer, bladder cancer, pancreatic cancer, stomach cancer, urothelial ...
Durvalumab
Durvalumab (Imfinzi) is an immunotherapy used to treat lung cancer (NSCLC, SCLC) and other cancers ...
Doxorubicin
Doxorubicin is used for acute lymphoblastic leukemia, acute myeloblastic leukemia, bladder cancer ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.